MyEG has finally sealed an agreement with Breathonix to be the exclusive distributor of its Covid-19 breath test system in Malaysia. As an alternative to the PCR testing, this will likely capture the rising inbound travelers due to its rapid result production. That said, we believe this exclusive agreement has largely been anticipated by the market, and has already been factored in into our estimates to a degree. As such we make no changes to our earnings forecast and TP of RM1.34. Maintain BUY.